The entire pharmaceutical industry is facing an indefinite period in 2005. Many of the most pressing issues in the industry - patent expiration, the development of new drug pipeline, the pressure on prices, regulatory issues, and political pressure - was long ago. Radically new technologies are changing the way drugs were discovered, developed and tested, allowing smaller, specialized competitors to enter the industry, competition in new ways, and to grow, to challenge the majors. Some observers even doubt that the blockbuster model, which was based industry can continue. Blockbuster, with sales of more than $ 1 billion a year, it is becoming more difficult and expensive to develop. In this regard, as well as stock prices depressed, industry specializations thinking about their strategies.
rewritten version of the previous case. "Hide
by John R. Wells, Elizabeth A. Raabe Source: Harvard Business School 21 pages. Publication Date: October 27, 2005. Prod. #: 706423-PDF-ENG
Related Case Solutions & Analyses:
Willow Creek Community Church: What Really Makes a Difference
Hiring at Huckle Buckle Beanstalk: Not All Fun and Games
Winning the Race With Ever-Smarter Machines
Pfizer: Letter from the Chairman (B)
Tyson Toles on Leadership
Directing Creativity: The Art and Craft of Leadership
Nestles Globe Program (A): The Early Months
Milliway Capital & Martin Smith: November 2008
BANG & OLUFSEN DESIGN DRIVEN INNOVATION
Brand Loyalty
